Analysts Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) to Announce $0.34 EPS
Equities research analysts forecast that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will announce earnings per share (EPS) of $0.34 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Sucampo Pharmaceuticals’ earnings. The lowest EPS estimate is $0.32 and the highest is $0.36. Sucampo Pharmaceuticals posted earnings of $0.68 per share in the same quarter last year, which would suggest a negative year over year growth rate of 50%. The firm is expected to report its next earnings report on Wednesday, March 14th.
According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full-year earnings of $1.12 per share for the current year, with EPS estimates ranging from $1.09 to $1.14. For the next financial year, analysts forecast that the firm will report earnings of $1.19 per share, with EPS estimates ranging from $1.05 to $1.36. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Sucampo Pharmaceuticals.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The company had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.30 EPS.
Several equities research analysts recently commented on SCMP shares. Maxim Group set a $23.00 target price on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. TheStreet downgraded shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Roth Capital set a $30.00 target price on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. BidaskClub downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 5th. Finally, Leerink Swann started coverage on shares of Sucampo Pharmaceuticals in a research report on Monday, August 21st. They set an “outperform” rating and a $15.00 target price on the stock. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $16.00.
In other news, major shareholder Sachiko Kuno sold 1,000,000 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jason Patrick Meyenburg purchased 4,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was purchased at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the transaction, the insider now directly owns 30,228 shares in the company, valued at approximately $366,665.64. The disclosure for this purchase can be found here. 4.13% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. HPM Partners LLC acquired a new position in shares of Sucampo Pharmaceuticals during the 2nd quarter valued at $1,307,000. Louisiana State Employees Retirement System lifted its position in shares of Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 100 shares during the period. Trexquant Investment LP acquired a new position in shares of Sucampo Pharmaceuticals during the 3rd quarter valued at $122,000. Nine Chapters Capital Management LLC acquired a new position in shares of Sucampo Pharmaceuticals during the 3rd quarter valued at $127,000. Finally, First Citizens Bank & Trust Co. acquired a new position in shares of Sucampo Pharmaceuticals during the 2nd quarter valued at $116,000. Institutional investors own 57.79% of the company’s stock.
Shares of Sucampo Pharmaceuticals (SCMP) opened at $10.55 on Friday. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a 1 year low of $9.30 and a 1 year high of $17.55. The company has a market cap of $485.01, a P/E ratio of 7.12, a P/E/G ratio of 3.10 and a beta of 1.38.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.